Argos Wealth Advisors LLC Purchases New Shares in Bristol Myers Squibb Company $BMY

Argos Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,600 shares of the biopharmaceutical company’s stock, valued at approximately $626,000.

Other large investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. raised its position in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $32,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Bristol Myers Squibb in the 3rd quarter worth about $35,000. Finally, Garner Asset Management Corp purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $35,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.4%

Bristol Myers Squibb stock opened at $56.46 on Wednesday. The business has a 50-day simple moving average of $58.95 and a two-hundred day simple moving average of $55.16. The company has a market cap of $115.30 billion, a P/E ratio of 15.86, a P/E/G ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.3 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb struck a large collaboration and licensing agreement with Hengrui Pharma covering 13 early-stage programs, including oncology, hematology, and immunology assets, which could strengthen the company’s pipeline and support future growth. Article Title
• Positive Sentiment: The deal includes substantial upfront and future milestone payments, signaling a meaningful commitment to the partnership and possible long-term value creation for Bristol Myers Squibb. Article Title
• Neutral Sentiment: Bristol Myers Squibb also reported that shareholders approved board and compensation matters, which appears routine and is unlikely to be a major driver of the stock today. Article Title
• Neutral Sentiment: One headline noted BMY shares had fallen for a seventh consecutive session before the latest strategic deal news, highlighting recent weakness that the Hengrui announcement may help offset. Article Title

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on BMY. Cantor Fitzgerald lifted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Royal Bank Of Canada began coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Finally, Barclays began coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.